FDA Puts Investigational FSHD Therapy Losmapimod on Fast Track

FDA Puts Investigational FSHD Therapy Losmapimod on Fast Track

294167

FDA Puts Investigational FSHD Therapy Losmapimod on Fast Track

The U.S. Food and Drug Administration (FDA) has granted fast track designation to losmapimod, a potential treatment for facioscapulohumeral muscular dystrophy (FSHD) being developed by Fulcrum Therapeutics. The designation is intended to help bring effective treatments for serious conditions to market more quickly. It grants Fulcrum, as the therapy’s developer, access to more frequent communications with the FDA throughout the drug development process. Fast track status also makes losmapimod eligible for other potential FDA designations,…

You must be logged in to read/download the full post.